查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2016242

呼吸道感染疾病治療市場：依治療方法、感染疾病類型、病患群體和給藥途徑分類－2026-2032年全球市場預測

Respiratory Tract Infection Therapeutic Market by Therapeutic Type, Infection Type, Patient Type, Route Of Administration - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年呼吸道感染疾病治療市值為514.5億美元，預計2026年將成長至547.4億美元，複合年成長率為8.20%，到2032年將達到893.4億美元。

主要市場統計數據
基準年 2025 514.5億美元
預計年份：2026年 547.4億美元
預測年份 2032 893.4億美元
複合年成長率 (%) 8.20%

概述當前呼吸道感染疾病治療現狀，並為臨床、監管和商業相關人員。

由於病原體進化、季節性變化以及醫療服務模式轉變等因素的複雜相互作用，呼吸道感染疾病仍然是臨床醫生、醫療系統和生物製藥公司面臨的持續挑戰。整體情況包括小分子抗生素和抗病毒藥物、止咳藥和減充血劑等症狀治療，以及調節宿主反應的抗發炎療法。本文概述了目前的治療現狀，並結合近期臨床和監管進展，為相關人員制定了確保治療成功的營運和策略重點。

找出正在重塑呼吸道感染疾病治療方法和護理路徑的科學、交付、監管和商業性轉折點。

呼吸治療領域正經歷一場變革，其驅動力來自科學進步、新型給藥平台以及對醫療保健體系變革的期待。分子診斷和快速就地檢驗正在加速病原體特異性治療方法的選擇，擴大抗病毒藥物的作用範圍，並減少經驗性抗生素的使用。這種診斷-臨床回饋循環正在重塑處方行為，並為標靶療法的研發開闢更清晰的路徑。

本研究分析了 2025 年的關稅環境將如何重塑採購經濟、供應鏈韌性以及呼吸系統治療藥物的臨床可用性。

2025年實施的最新關稅政策增加了藥品和醫療設備供應鏈的複雜性，對治療藥物的可近性、生產經濟性和籌資策略產生了切實的影響。關稅造成的成本差異不僅影響成品，也影響活性藥物成分、輔料和吸入裝置專用組件。這些成本壓力迫使製造商重新評估籌資策略，優先選擇免稅地區的供應商，並考慮在區域內生產，以維持獲利能力並確保供應的連續性。

我們將分析治療領域、感染部位、患者人口統計特徵和給藥途徑，以確定差異化的臨床和商業性需求。

一套精細的細分框架揭示了不同治療領域和患者群體的需求和發展促進因素。重點治療領域包括抗生素、抗病毒藥物、止咳藥、減充血劑和非類固醇消炎劑（NSAIDs）。抗生素進一步細分為Fluoroquinolones、大環內酯類、青黴素類和四環黴素，以反映其抗菌頻譜、抗藥性考量和製劑策略。這些治療領域的區分為確定研發重點、合理用藥政策和市場定位提供了關鍵指南。

本研究分析了美洲、歐洲、中東和非洲以及亞太地區區域性醫療保健生態系統和法規環境如何影響治療方法的採用和打入市場策略。

區域趨勢對美洲、歐洲、中東和非洲以及亞太地區的臨床實踐模式、監管路徑和商業性模式有顯著影響。在美洲，醫療保健系統優先考慮快速診斷、醫院藥物使用計劃和協商式合約結構。這種環境有利於那些能夠顯著縮短住院時間並對醫療管理機構具有明確價值提案的療法。公共採購政策與私部門合約之間的互動要求贊助商提供靈活的商業模式，以適應醫療保健和門診環境。

本研究評估了成熟的製藥公司、創新生物技術公司、學名藥生產商和醫療設備專家如何塑造呼吸系統治療領域的競爭與合作。

呼吸系統治療領域的競爭動態呈現出多元化的特點，大型跨國公司、專業生物技術公司、學名藥生產商和醫療設備創新者各自探索著實現臨床和商業性價值的道路。成熟的製藥公司利用其規模優勢、廣泛的分銷網路以及與現有處方藥目錄（配方）的合作關係，支持現有藥物的生命週期管理，並投資於下一代給藥平台。同時，中小型生物技術公司正積極推動新型抗病毒藥物、宿主反應調節劑和標靶生物製劑的創新，它們通常透過與大型商業夥伴建立策略夥伴關係和許可協議來開發產品。

為贊助商制定可行的跨部門策略，以協調開發、生產和市場進入工作，從而最大限度地提高臨床部署率並最大限度地降低供應風險。

產業領導者應優先考慮制定整合策略，將研發投資與供應鏈韌性以及符合支付方需求的證據產生結合。首先，他們需要加速研發進程，採用快速診斷和適應性試驗設計來驗證治療的特異性和實際效益。這將有助於在日益重視標靶干預和可衡量結果的環境中實現更清晰的差異化。

嚴謹的混合方法研究框架，結合臨床專家見解、供應鏈分析、監管審查和真實世界證據三角驗證，得出可靠的結論。

本分析的研究方法基於多方法框架，整合了第一手和第二手調查數據，以整體情況。主要資料來源包括對臨床意見領袖、供應鏈主管和支付方代表的結構化訪談，以及針對處方醫生和醫院採購經理的定向問卷調查。這些定性研究結果與監管申報文件、臨床試驗註冊資訊和同行評審文獻進行交叉比對，以檢驗趨勢並識別新的作用機制和給藥創新。

全面概述了透過與支付方合作，將科學創新、供應韌性和證據生成整合起來，作為呼吸系統治療領域持續成功的支柱。

這些章節中提出的綜合分析強調了在科學創新、供應鏈發展以及與支付方建立夥伴關係方面開展合作的必要性，以有效應對呼吸道感染疾病。治療的成功越來越依賴診斷、個人化配方和給藥技術的整合，這些技術既要滿足不同患者群體的需求，又要符合抗菌藥物管理的要求。生產和採購的韌性，以及靈活的商業模式，將在應對政策主導的成本壓力和不斷變化的採購趨勢方面發揮關鍵作用。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 呼吸道感染疾病治療市場：依治療類型分類

  • 抗生素
    • Fluoroquinolones
    • 大環內酯類
    • 青黴素
    • 四環黴素
  • 抗病毒藥物
  • 止咳藥
  • 緩解鼻塞的藥物
  • 非類固醇消炎劑

第9章 呼吸道感染疾病治療藥物市場（依感染疾病類型分類）

  • 下呼吸道感染疾病
  • 上呼吸道感染疾病

第10章 依患者類型分類的呼吸道感染疾病治療藥物市場

  • 成人
  • 老年人
  • 兒童

第11章 呼吸道感染疾病治療藥物市場：依給藥途徑分類

  • 吸入
    • 定量噴霧吸入器
    • 噴霧器
  • 口服
    • 懸浮液
    • 藥片
  • 腸外

第12章 呼吸道感染疾病治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 呼吸道感染疾病治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 呼吸道感染疾病治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國呼吸道感染疾病治療市場

第16章：中國呼吸道感染疾病治療藥物市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Alkem Laboratories Limited
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Cadila Healthcare Limited
  • Cipla Limited
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Limited
  • Hikma Pharmaceuticals PLC
  • Intas Pharmaceuticals Limited
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan Inc. by Viatris Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi SA
  • Steris Healthcare Pvt. Ltd.
  • Teva Pharmaceutical Industries Ltd
Product Code: MRR-035AB9C0DAC8

The Respiratory Tract Infection Therapeutic Market was valued at USD 51.45 billion in 2025 and is projected to grow to USD 54.74 billion in 2026, with a CAGR of 8.20%, reaching USD 89.34 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 51.45 billion
Estimated Year [2026] USD 54.74 billion
Forecast Year [2032] USD 89.34 billion
CAGR (%) 8.20%

Framing the contemporary respiratory tract infection therapeutic environment and establishing strategic priorities for clinical, regulatory, and commercial stakeholders

Respiratory tract infections remain a perennial challenge for clinicians, health systems, and biopharma sponsors, driven by a complex interplay of pathogen evolution, seasonal dynamics, and shifting care delivery models. The therapeutic landscape spans small-molecule antibiotics and antivirals, symptomatic agents such as cough suppressants and nasal decongestants, and anti-inflammatory therapies that modulate host response. This overview situates the current therapeutic environment within recent clinical and regulatory developments while framing the operational and strategic priorities that stakeholders must address to succeed.

As antimicrobial stewardship intensifies and precision medicine approaches gain traction, therapeutic decision-making increasingly balances rapid diagnostics, targeted therapies, and patient-centered outcomes. Concurrently, advances in inhalation technology, formulation science, and biologics are reshaping how treatments are administered and evaluated. These factors together reconfigure clinical pathways and commercial considerations, demanding integrated strategies that connect R&D, regulatory affairs, manufacturing, and market access.

This introduction sets the stage for a focused examination of transformative shifts, tariff-related supply chain implications, key segmentation drivers, regional nuances, competitive intelligence, actionable recommendations, and the methodological rigor behind the analysis. Readers will find a synthesis that highlights both immediate operational levers and longer-term strategic imperatives for therapeutic stakeholders.

Identifying the scientific, delivery, regulatory, and commercial inflection points that are remaking respiratory tract infection therapeutics and care pathways

The respiratory therapeutics landscape is undergoing a period of transformation driven by scientific advances, novel delivery platforms, and evolving health system expectations. Molecular diagnostics and rapid point-of-care testing are accelerating pathogen-specific treatment selection, which augments the role of antivirals and narrows empirical antibiotic use. This diagnostic-clinical feedback loop is reshaping prescribing behavior and creating clearer pathways for targeted therapeutic development.

At the same time, innovations in drug delivery-particularly inhalation devices and reformulated oral suspensions-are enabling improved adherence, faster onset of action, and novel indications for existing molecules. Biologics and host-directed therapies are emerging as complementary approaches to traditional antimicrobials, offering the potential to mitigate severe disease and reduce hospitalization rates. Regulatory frameworks are adapting to accommodate these modalities, with increased emphasis on real-world evidence and post-approval safety monitoring.

Commercially, payers and providers are prioritizing value-based approaches that link clinical outcomes to reimbursement, prompting sponsors to demonstrate not just efficacy but measurable improvements in patient-centric endpoints and health-system resource utilization. As a result, agility in clinical development, manufacturing, and evidence generation has become a competitive differentiator, requiring cross-functional coordination and sustained investment in translational science.

Analyzing how the 2025 tariff landscape is reshaping procurement economics, supply chain resilience, and clinical availability for respiratory therapeutics

Recent tariff policies enacted in 2025 have introduced a new layer of complexity into pharmaceutical and device supply chains, with tangible implications for therapeutic availability, manufacturing economics, and procurement strategies. Tariff-induced cost differentials affect not only finished products but also active pharmaceutical ingredients, excipients, and specialized components for inhalation devices. These cost pressures compel manufacturers to reassess sourcing strategies, prioritize supplier qualification in tariff-exempt jurisdictions, and explore in-region production to preserve margin and ensure supply continuity.

Clinically, any disruption to supply or sudden cost increases for preferred formulations can prompt shifts in prescribing patterns, particularly in acute care settings where treatment decisions are time sensitive. Hospitals and health systems may adjust formularies to favor therapeutics with stable procurement channels, while contract negotiations with group purchasing organizations will increasingly incorporate tariff exposure as a risk variable. For companies, this heightens the importance of transparent cost modeling and proactive engagement with payers to negotiate reimbursement pathways that reflect new cost structures.

Policy responses and private-sector mitigation strategies are evolving in parallel. Companies are accelerating efforts to localize manufacturing capacity in tariffs-aligned regions and to diversify supplier networks. Strategic inventory management and forward-buy agreements offer short-term buffers, but long-term resilience depends on flexible production architectures, modular manufacturing investments, and partnership models that distribute risk across geographically diverse sites. Overall, tariff developments in 2025 underscore the strategic imperative for integrated supply chain intelligence and adaptive commercial planning.

Dissecting therapeutic class, infection locus, patient demographics, and administration routes to reveal differentiated clinical and commercial imperatives

A nuanced segmentation framework reveals the varying drivers of demand and development across therapeutic and patient categories. Based on therapeutic type, attention centers on antibiotics, antivirals, cough suppressants, nasal decongestants, and non-steroidal anti-inflammatory drugs, with antibiotics further differentiated into fluoroquinolones, macrolides, penicillins, and tetracyclines to reflect spectrum of activity, resistance considerations, and formulation strategies. These therapeutic distinctions inform development priorities, stewardship policies, and commercial positioning.

Based on infection type, differentiating lower respiratory tract infections from upper respiratory tract infections clarifies clinical trial design, endpoint selection, and target populations since disease severity, hospitalization risk, and diagnostic pathways diverge significantly between these categories. Based on patient type, tailoring approaches for adults, geriatrics, and pediatrics is essential because pharmacokinetics, comorbidity profiles, and adherence behaviors vary across age cohorts, influencing dosing strategies and formulation choices.

Based on route of administration, the clinical and commercial landscapes are shaped by inhalation, oral, and parenteral options; inhalation modalities are further subdivided into metered dose inhalers and nebulizers, while oral delivery includes liquid suspensions and tablets to accommodate different patient needs and compliance realities. These route distinctions drive device partnerships, stability and excipient development, and distribution considerations. Collectively, this segmentation underscores the importance of integrated product strategies that align therapeutic class, infection locus, patient demographics, and delivery modality to optimize clinical impact and market adoption.

Unpacking how divergent regional healthcare ecosystems and regulatory environments across the Americas, Europe Middle East & Africa, and Asia-Pacific shape therapeutic adoption and market entry strategies

Regional dynamics materially influence clinical practice patterns, regulatory pathways, and commercial approaches across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, health systems emphasize rapid diagnostics, hospital stewardship programs, and negotiated contracting structures; these conditions favor therapeutics that demonstrate measurable reductions in length of stay and clear value propositions for managed care organizations. The interplay between public procurement policies and private sector contracting requires sponsors to present flexible commercial models adapted to both institutional and outpatient settings.

In Europe, Middle East & Africa, regulatory harmonization across subregions coexists with diverse reimbursement environments, which places a premium on local evidence generation and targeted payer engagement. Countries with established antimicrobial stewardship initiatives demand robust safety and resistance mitigation data, while emerging markets within the region present opportunities for scaled access strategies by addressing affordability and supply chain constraints.

Asia-Pacific displays heterogeneity that spans advanced markets with stringent regulatory expectations to high-growth markets where access and distribution challenges persist. Rapid urbanization, varied healthcare financing models, and differing disease prevalence patterns necessitate differentiated market entry tactics, including local partnerships, adaptive pricing mechanisms, and investments in diagnostic-enabled care pathways. Adapting to these regional nuances enhances the probability of successful adoption and sustained commercial performance.

Evaluating how incumbent pharmaceutical players, innovative biotech firms, generics producers, and device specialists are shaping competition and collaboration in respiratory therapeutics

Competitive dynamics in respiratory therapeutics are characterized by a mix of large multinational firms, specialized biotechs, generics manufacturers, and device innovators, each pursuing distinct routes to clinical and commercial relevance. Established pharmaceutical companies leverage scale, broad distribution networks, and existing formulary relationships to support lifecycle management of legacy molecules and invest in next-generation delivery platforms. Meanwhile, small and mid-sized biotech firms drive innovation in novel antivirals, host-response modulators, and targeted biologics, often advancing assets through strategic partnerships or licensing agreements with larger commercial partners.

Generics and biosimilar entrants apply cost-efficiency and supply reliability as differentiators, responding to stewardship-driven pressures that favor narrow-spectrum or lower-cost options in certain clinical situations. Device manufacturers and contract development and manufacturing organizations contribute critical capabilities for inhalation technology, novel excipients, and scalable sterile production, positioning themselves as essential collaborators for sponsors seeking rapid market entry. Across the ecosystem, successful companies are those that align clinical development with pragmatic commercial strategies, demonstrate regulatory agility, and invest in real-world evidence to support differentiated value claims.

Actionable cross-functional strategies for sponsors to align development, manufacturing, and market access efforts to maximize clinical adoption and minimize supply risks

Industry leaders should prioritize integrated strategies that align R&D investments with supply chain resilience and payer-aligned evidence generation. First, accelerate development pathways that incorporate rapid diagnostics and adaptive trial designs to demonstrate therapeutic specificity and real-world clinical benefit. Doing so will enable clearer differentiation in an environment that increasingly values targeted interventions and measurable outcomes.

Second, build geographically diversified manufacturing and sourcing footprints to mitigate tariff exposure and logistical disruption. Investing in modular production capabilities and qualifying alternate suppliers reduces operational risk and supports continuity of supply, which is a critical factor for hospital and system-level adoption. Third, engage proactively with payers and health systems to co-design reimbursement frameworks that reward demonstrated improvements in clinical outcomes and resource utilization. Structured real-world evidence programs and outcomes-based contracting can bridge initial cost concerns and establish long-term reimbursement pathways.

Finally, cultivate cross-sector partnerships that combine therapeutic innovation with advanced delivery platforms and diagnostics. Collaborative models that share development risk and align commercial incentives will accelerate adoption and improve patient outcomes, while also distributing the capital burden of bringing complex therapies to market.

A rigorous mixed-methods research framework combining clinical expert insight, supply chain analysis, regulatory review, and real-world evidence triangulation to ensure robust conclusions

The research approach underpinning this analysis relies on a multi-method framework that integrates primary and secondary evidence to generate a holistic view of the respiratory therapeutics landscape. Primary inputs include structured interviews with clinical opinion leaders, supply chain executives, and payer representatives, combined with targeted surveys of prescribers and hospital procurement leads. These qualitative insights are triangulated with regulatory filings, clinical trial registries, and peer-reviewed literature to validate trends and identify emerging mechanisms of action and delivery innovations.

Complementary analyses examine manufacturing footprints, tariff schedules, and procurement practices to assess operational vulnerabilities and mitigation strategies. The methodology emphasizes transparency in source attribution, reproducibility of analytic steps, and sensitivity testing of key assumptions. Limitations are acknowledged, including the dynamic nature of policy decisions and the variability of clinical practice across jurisdictions, and the report highlights areas where ongoing surveillance and iterative evidence collection will be most valuable. This robust, mixed-methods approach ensures that conclusions are grounded in both technical expertise and practical, real-world perspectives.

Concluding synthesis that integrates scientific innovation, supply resilience, and payer-aligned evidence generation as the pillars of durable success in respiratory therapeutics

The synthesis presented across these sections emphasizes that addressing respiratory tract infections effectively requires coordinated action across scientific innovation, supply chain architecture, and payer engagement. Therapeutic success increasingly depends on the integration of diagnostics, tailored formulations, and delivery technologies that meet the needs of distinct patient cohorts while satisfying stewardship imperatives. Resilience in manufacturing and sourcing, along with adaptive commercial models, will be decisive in navigating policy-driven cost pressures and procurement shifts.

Strategic focus on evidence generation that aligns with payer priorities, paired with targeted regional strategies, will enable sponsors to translate clinical efficacy into tangible healthcare value. In turn, collaborative partnerships between innovators, device developers, and healthcare providers can accelerate patient access and improve outcomes. The concluding perspective underscores that the combination of clinical rigor, operational resilience, and commercially savvy engagement forms the foundation for sustainable success in respiratory tract infection therapeutics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Respiratory Tract Infection Therapeutic Market, by Therapeutic Type

  • 8.1. Antibiotics
    • 8.1.1. Fluoroquinolones
    • 8.1.2. Macrolides
    • 8.1.3. Penicillins
    • 8.1.4. Tetracyclines
  • 8.2. Antivirals
  • 8.3. Cough Suppressants
  • 8.4. Nasal Decongestants
  • 8.5. Non-Steroidal Anti-Inflammatory Drugs

9. Respiratory Tract Infection Therapeutic Market, by Infection Type

  • 9.1. Lower Respiratory Tract Infection
  • 9.2. Upper Respiratory Tract Infection

10. Respiratory Tract Infection Therapeutic Market, by Patient Type

  • 10.1. Adults
  • 10.2. Geriatrics
  • 10.3. Pediatrics

11. Respiratory Tract Infection Therapeutic Market, by Route Of Administration

  • 11.1. Inhalation
    • 11.1.1. Metered Dose Inhalers
    • 11.1.2. Nebulizers
  • 11.2. Oral
    • 11.2.1. Liquid Suspensions
    • 11.2.2. Tablets
  • 11.3. Parenteral

12. Respiratory Tract Infection Therapeutic Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Respiratory Tract Infection Therapeutic Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Respiratory Tract Infection Therapeutic Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Respiratory Tract Infection Therapeutic Market

16. China Respiratory Tract Infection Therapeutic Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Alkem Laboratories Limited
  • 17.7. AstraZeneca PLC
  • 17.8. Boehringer Ingelheim GmbH
  • 17.9. Cadila Healthcare Limited
  • 17.10. Cipla Limited
  • 17.11. F. Hoffmann-La Roche AG
  • 17.12. GlaxoSmithKline plc
  • 17.13. Glenmark Pharmaceuticals Limited
  • 17.14. Hikma Pharmaceuticals PLC
  • 17.15. Intas Pharmaceuticals Limited
  • 17.16. Lupin Limited
  • 17.17. Merck & Co., Inc.
  • 17.18. Mylan Inc. by Viatris Inc.
  • 17.19. Novartis International AG
  • 17.20. Pfizer Inc.
  • 17.21. Sanofi S.A.
  • 17.22. Steris Healthcare Pvt. Ltd.
  • 17.23. Teva Pharmaceutical Industries Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY FLUOROQUINOLONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY FLUOROQUINOLONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PENICILLINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PENICILLINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUGH SUPPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUGH SUPPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUGH SUPPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NASAL DECONGESTANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NASAL DECONGESTANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NASAL DECONGESTANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY GERIATRICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY GERIATRICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY GERIATRICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PEDIATRICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY METERED DOSE INHALERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY METERED DOSE INHALERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY METERED DOSE INHALERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NEBULIZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NEBULIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LIQUID SUSPENSIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LIQUID SUSPENSIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LIQUID SUSPENSIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 146. GCC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GCC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. GCC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 149. GCC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. GCC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. GCC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. GCC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 153. GCC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 170. G7 RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. G7 RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. G7 RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 173. G7 RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. G7 RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. G7 RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 176. G7 RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 177. G7 RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 178. NATO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. NATO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. NATO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 181. NATO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. NATO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. NATO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. NATO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 185. NATO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)